Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stepwise SOM230-based medical treatment for Cushing's disease
NL-OMON20587Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2007
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of pasireotide LAR, cabergoline, ketoconazole in Corticotropin adenoma (ACTHoma), sponsored by Erasmus MC. Started Sep 2007; status: recruiting.
02
Drugs
pasireotide LARcabergolineketoconazole
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on NL-OMON20587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20587.